**TERMS OF REFERENCE**

***XX HOSPITAL* ANTIMICROBIAL STEWARDSHIP COMMITTEE**

1. **Purpose**

The *XX HOSPITAL* Antimicrobial Stewardship (AMS) Committee will provide oversight and input into the development, implementation and ongoing review of the AMS program at *XX HOSPITAL*. The AMS program will involve a systematic approach to optimising the use of antimicrobials in *XX HOSPITAL* in order to improve patient outcomes, reduce inappropriate antimicrobial use, and reduce adverse consequences of antimicrobial use (including antimicrobial resistance, toxicity and unnecessary costs).[[1]](#footnote-1)

1. **Responsibilities and Activities**

The *XX HOSPITAL* AMS Committee will provide high level advice and decision making with regards to the overall approach to optimising antimicrobial use, and specific strategies to improve antimicrobial prescribing in *XX HOSPITAL*.

These strategies include, but are not limited to:

* The use of clinical guidelines consistent with the latest version of *Therapeutic Guidelines: Antibiotic*, taking into account local microbiology and antimicrobial susceptibility patterns;
* The use of formulary restriction and approval systems for broad-spectrum and later generation antimicrobials to limit use to patients in whom their use is clinically justified;
* Review of antimicrobial prescribing with intervention and direct feedback to the prescriber;
* Systems to monitor antimicrobial usage and resistance, such as provision of antimicrobial usage reports and other indicators of performance for the AMS program;
* The use of selective reporting of susceptibility testing results by the clinical microbiology service, consistent with the antimicrobial formulary and guidelines;
* Education of prescribers, pharmacists and nurses about good antimicrobial prescribing practice and antimicrobial resistance;
* The use of point-of-care interventions, including streamlining or de-escalation of therapy, dose optimisation or parenteral-to-oral conversion.1

These strategies are consistent with the recommendations of the Australian Commission on Safety and Quality in Healthcare and the Clinical Excellence Commission. These strategies will support the requirements of the National Safety and Quality Health Service Standards, specifically criterion 3.14, Antimicrobial stewardship.

The core activities of this committee include:

* To review, endorse and plan implementation of clinical guidelines for antimicrobial prescribing;
* To develop, endorse and plan implementation of the restriction of selected antimicrobial agents in liaison with the *XX HOSPITAL* Drug and Therapeutics Committee;
* To develop, endorse and plan implementation of systems to review antimicrobial prescribing and feedback results to prescribers;
* To develop, endorse and plan implementation of systems to monitor antimicrobial usage and resistance;
* To liaise with clinical microbiology services in *XX HOSPITAL* to ensure selective reporting of susceptibility testing results is in place and aligns with the antimicrobial formulary and guidelines;
* To review, endorse and plan implementation of an education program for good antimicrobial prescribing practice and antimicrobial resistance, in liaison with clinical educators in *XX HOSPITAL*;
* To develop, endorse and plan implementation of resources to support point-of-care interventions;
* To monitor the effectiveness of strategies used in the AMS program at *XX HOSPITAL*, including the review of relevant reports and key performance indicators;
* To plan action, including risk assessment, to improve the effectiveness of the AMS program at *XX HOSPITAL*.

1. **Organisational Risks Addressed by this Committee**

The key risks to the organisation that will be managed by this Committee include:

* Risks associated with inappropriate use of antimicrobials (including antimicrobial resistance, toxicity and unnecessary costs);
* Conflict that may arise from formulary restrictions and/or performance measures based on concordance with clinical guidelines.

Antimicrobial stewardship is a key strategy in the prevention and management of healthcare associated infections (HAI). The *XX HOSPITAL* AMS Committee will report to the *XX HOSPITAL* Infection Prevention Control Committee to facilitate the oversight of HAI risks that are linked to antimicrobial use, e.g. *Clostridium difficile* infections.

1. **Membership and roles**

All members are expected to play an active role in the development, implementation and review of AMS strategies at *XX HOSPITAL*. Members represent their unit, department or discipline, and as such, may liaise with staff in their unit when broad input is needed e.g. development of a protocol for a specific infectious condition. Members are also expected to champion the AMS program in their own unit, and demonstrate leadership for AMS in their prescribing practices, as well as in their knowledge and attitudes.

Membership of the AMS committee will consist of:

* Director Clinical Governance or General Manager (Executive Sponsor/Chair)
* Director Medical Services (Deputy Chair)
* Infectious diseases physician and/or clinical microbiologist (AMS lead)
* AMS Pharmacist (Secretary)
* Patient Safety and Clinical Quality Manager
* Nursing representatives *<insert relevant position/s>*
* Pharmacy representatives *<insert relevant position/s>*
* Medical staff representatives (Respiratory, Haematology, Emergency, Surgery, Critical Care, General Practitioner)
* Pathology representatives (Microbiology)
* Consumer representative
* *XX HOSPITAL* Drug and Therapeutics Committee representative
* *XX HOSPITAL* Infection Prevention Control Committee representative
* *XX HOSPITAL* Medication Safety Committee representative.

Other personnel may be co-opted as required to assist the work of the Committee.

1. **Quorum**

A quorum, consisting of half the number of member plus one, must be in attendance for decision-making.

1. **Frequency of Meeting**

The meetings will be held monthly, onthe <*insert*> of the month.

The meetings will be set at the beginning of each calendar year and circulated to members.

1. **Agenda Preparation and Minutes Circulation**

Papers for the committee will be prepared by the *XX HOSPITAL* AMS Committee Secretary and circulated one week prior to the meeting date.

The agenda will be determined by the *XX HOSPITAL* AMS Committee Chair prior to meetings. Agenda items must be forwarded to the *XX HOSPITAL* AMS Committee Secretary at least one week prior to circulation of the agenda, i.e. two weeks before the next meeting.

Minutes will be distributed to members within two weeks of the meeting date by the *XX HOSPITAL* AMS Committee Secretary.

In addition to committee members, Minutes will be made available to:

* *XX HOSPITAL* Drug and Therapeutics Committee
* *XX HOSPITAL* Infection Prevention Control Committee
* *XX HOSPITAL* Medication Safety Committee
* *XX HOSPITAL* Quality Committee.

1. **Confidentiality**

Matters discussed at AMS Committee meetings may be of a confidential nature and must be treated as such by members. Committee materials, proposals, business cases and procurement decisions that come into a committee member’s possession must only be used or disclosed for the purpose of the AMS Committee function. To protect confidentiality, individual members must destroy all proposals or information (electronic or paper form) provided in a secure way once the purposes for which it was provided have been fulfilled.

1. **Reporting Lines**

The Minutes of the committee will be forwarded through the *XX HOSPITAL* Drug and Therapeutics Committee to *XX HOSPITAL* Health Care Quality Committee.

A quarterly report will be prepared outlining:

* Gap analyses or risk assessments undertaken to direct strategies for the AMS program;
* Reports reviewed by the committee relevant to the AMS program e.g. antimicrobial usage reports;
* Action taken by the committee (i.e. reviews undertaken, resources developed, items endorsed, planning, liaison with key stakeholders for antimicrobial prescribing).

The committee will review and endorse reports and activities of working parties or subcommittees as required.

1. **Evaluation/Key Performance Indicators**

* Publication and distribution of *XX HOSPITAL* AMS Committee Quarterly Reports
* Meeting frequency and attendance in accordance with terms of reference
* Monitoring *XX HOSPITAL* performance against the National Safety and Quality Health Service Standards, specifically criterion 3.14, Antimicrobial stewardship.
* Development of key performance indicators for the *XX HOSPITAL* AMS program within 12 months of establishing the *XX HOSPITAL* AMS Committee.

1. **Review**

The Terms of Reference will be reviewed annually.

Page 3

1. Duguid M, Cruickshank M (eds). 2010. Antimicrobial stewardship in Australian hospitals. Australian Commission on Safety and Quality in Healthcare: Sydney. [↑](#footnote-ref-1)